Advertisement
Canada markets close in 3 hours 11 minutes
  • S&P/TSX

    22,042.71
    +170.75 (+0.78%)
     
  • S&P 500

    5,070.84
    +60.24 (+1.20%)
     
  • DOW

    38,497.86
    +257.88 (+0.67%)
     
  • CAD/USD

    0.7316
    +0.0015 (+0.20%)
     
  • CRUDE OIL

    83.02
    +1.12 (+1.37%)
     
  • Bitcoin CAD

    91,282.92
    +850.98 (+0.94%)
     
  • CMC Crypto 200

    1,434.50
    +19.74 (+1.39%)
     
  • GOLD FUTURES

    2,342.50
    -3.90 (-0.17%)
     
  • RUSSELL 2000

    2,002.89
    +35.42 (+1.80%)
     
  • 10-Yr Bond

    4.5840
    -0.0390 (-0.84%)
     
  • NASDAQ

    15,694.01
    +242.70 (+1.57%)
     
  • VOLATILITY

    16.27
    -0.67 (-3.95%)
     
  • FTSE

    8,044.81
    +20.94 (+0.26%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6836
    -0.0014 (-0.20%)
     

Puma Biotechnology: Recent Developments and Recommendations

Puma Biotechnology: Recent Developments and Recommendations

In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.